Proteologics is a biopharmaceutical company exploiting the UBIQUITIN system for the discovery and development of novel therapeutics. Drs. Avram Hershko and Aaron Ciechanover, - 2004 Nobel Prize in Chemistry laureates for the discovery of the ubiquitin system - lead our distinguished scientific advisory board. Proteologics world-class knowledge, supported by a unique target and drug discovery platform, is being used to unveil the role of ubiquitin in pathologies with the goal of developing ubiquitin system targeted drugs.

Proteologics focuses primarily on discovering inhibitors for specific ubiquitin enzymes - E3 ligases - and their interacting proteins. These enzymes, which control the regulation of protein breakdown, are known to play key roles in a variety of cell cycle and viral processes. E3's are believed to offer novel drug targets for cancer, viral infections like flu & HIV and CNS related disorders. Proteologics has four discovery programs backed by venture capital funding and collaborations with industrial and academic institutions. The company is identifying novel, broad-spectrum antiviral drugs to provide more effective treatment against drug-resistant HIV, a variety of influenza strains and other viruses. In parallel, the company is developing therapeutic agents to interfere at specific ubiquitin pathway sites relevant to a number of cancer tumor types. Two of our cancer projects are developed in collaboration with Teva Pharmaceutical Industries Ltd.

 

.